Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion type Assertion NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_head.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion description "[Despite increasing use of 'targeted therapy,' interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion evidence source_evidence_literature NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion SIO_000772 21577143 NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion wasDerivedFrom befree-20150227 NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.
- NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_assertion wasGeneratedBy ECO_0000203 NP493102.RAEnbWkxrsk3VLV07UZ9h86iJrbuC_T35pSSKaJ_ibl1Q130_provenance.